150 related articles for article (PubMed ID: 19667983)
1. Monitoring of minimal residual disease in acute myeloid leukemia.
Buccisano F; Maurillo L; Spagnoli A; Del Principe MI; Ceresoli E; Lo Coco F; Arcese W; Amadori S; Venditti A
Curr Opin Oncol; 2009 Nov; 21(6):582-8. PubMed ID: 19667983
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
Zwick D; Cooley L; Hetherington M
Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in acute myeloid leukaemia.
Liu Yin JA
Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
[TBL] [Abstract][Full Text] [Related]
5. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
6. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
Freeman SD; Jovanovic JV; Grimwade D
Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Bacher U; Kern W; Schoch C; Schnittger S; Hiddemann W; Haferlach T
Cancer; 2006 Feb; 106(4):839-47. PubMed ID: 16419072
[TBL] [Abstract][Full Text] [Related]
9. Detection of minimal residual disease in acute leukemia patients.
van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
[TBL] [Abstract][Full Text] [Related]
10. [Detection of minimal residual disease by means of FISH and PCR methods and its clinical evaluation].
Misawa S; Taniwaki M; Yokota S
Rinsho Ketsueki; 1995 Apr; 36(4):293-8. PubMed ID: 7783332
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
12. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
Campana D
Curr Opin Hematol; 2012 Jul; 19(4):313-8. PubMed ID: 22525580
[TBL] [Abstract][Full Text] [Related]
14. Monitoring minimal residual disease in AML: the right time for real time.
Jaeger U; Kainz B
Ann Hematol; 2003 Mar; 82(3):139-47. PubMed ID: 12634945
[TBL] [Abstract][Full Text] [Related]
15. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
San-Miguel JF; Vidriales MB; Orfão A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):105-18. PubMed ID: 11987919
[TBL] [Abstract][Full Text] [Related]
16. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
